RxDoctor Payments Data

Cynthia Antonio

Family · Orange, CANPI 1962745554

Payments from drug & device makers

$6,770in general payments, 2019–2025

Across 378 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Mannkind Corporation$707
  • Novo Nordisk$646
  • Amgen$538
  • AstraZeneca$425
  • Embecta Corp.$242
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,746100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,770 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$86,127
TrulicityDulaglutide26$46,904
FarxigaDapagliflozin Propanediol42$44,992
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$30,675
JardianceEmpagliflozin18$29,627
MounjaroTirzepatide17$25,014
JanuviaSitagliptin Phosphate17$16,394
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,640
Tresiba Flextouch U-100Insulin Degludec13$6,104
Humalog Kwikpen U-100Insulin Lispro25$6,035
Nano 2nd Gen Pen NeedlePen Needle, Diabetic32$4,015
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$1,845
Levothyroxine Sodium65$1,792
SynthroidLevothyroxine Sodium18$1,718
Pioglitazone Hcl57$972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$646$86,12769 claims
Lilly USA, LLCTrulicity, Mounjaro$1,441$71,91843 claims
AstraZenecaFarxiga$425$44,99242 claims
Boehringer IngelheimJardiance$213$29,62718 claims
MerckJanuvia$99$16,39417 claims
AbbVieSynthroid$242$1,71818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →